Zobrazeno 1 - 10
of 87
pro vyhledávání: '"David Gilot"'
Autor:
Kevin Bévant, Matthis Desoteux, Gaëlle Angenard, Raphaël Pineau, Stefano Caruso, Corentin Louis, Panagiotis Papoutsoglou, Laurent Sulpice, David Gilot, Jessica Zucman‐Rossi, Cédric Coulouarn
Publikováno v:
Hepatology Communications, Vol 6, Iss 5, Pp 1157-1171 (2022)
Transforming growth factor beta (TGF‐β) plays a key role in tumor progression, notably as a potent inducer of epithelial–mesenchymal transition (EMT). However, all of the molecular effectors driving TGFβ‐induced EMT are not fully characterize
Externí odkaz:
https://doaj.org/article/88f8ea927575427898d86aa5d00ead50
Autor:
Serena Diazzi, Alberto Baeri, Julien Fassy, Margaux Lecacheur, Oskar Marin‐Bejar, Christophe A Girard, Lauren Lefevre, Caroline Lacoux, Marie Irondelle, Carine Mounier, Marin Truchi, Marie Couralet, Mickael Ohanna, Alexandrine Carminati, Ilona Berestjuk, Frederic Larbret, David Gilot, Georges Vassaux, Jean‐Christophe Marine, Marcel Deckert, Bernard Mari, Sophie Tartare‐Deckert
Publikováno v:
EMBO Molecular Medicine, Vol 14, Iss 3, Pp n/a-n/a (2022)
Abstract Lineage dedifferentiation toward a mesenchymal‐like state displaying myofibroblast and fibrotic features is a common mechanism of adaptive and acquired resistance to targeted therapy in melanoma. Here, we show that the anti‐fibrotic drug
Externí odkaz:
https://doaj.org/article/671e1303a548439c811055b9bfe4b17f
Autor:
Arthur Gautron, Laura Bachelot, Marc Aubry, Delphine Leclerc, Anaïs M Quéméner, Sébastien Corre, Florian Rambow, Anaïs Paris, Nina Tardif, Héloïse M Leclair, Oskar Marin‐Bejar, Cédric Coulouarn, Jean‐Christophe Marine, Marie‐Dominique Galibert, David Gilot
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 5, Pp n/a-n/a (2021)
Abstract Most genetic alterations that drive melanoma development and resistance to targeted therapy have been uncovered. In contrast, and despite their increasingly recognized contribution, little is known about the non‐genetic mechanisms that dri
Externí odkaz:
https://doaj.org/article/aca2254b33d042efb8994b39d40584e3
Autor:
Sébastien Corre, Nina Tardif, Nicolas Mouchet, Héloïse M. Leclair, Lise Boussemart, Arthur Gautron, Laura Bachelot, Anthony Perrot, Anatoly Soshilov, Aljosja Rogiers, Florian Rambow, Erwan Dumontet, Karin Tarte, Alban Bessede, Gilles J. Guillemin, Jean-Christophe Marine, Michael S. Denison, David Gilot, Marie-Dominique Galibert
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Resistance to BRAF inhibitors limits their clinical benefit in melanoma patients. Here, the authors show that the Aryl hydrocarbon Receptor (AhR) is a key mediator of resistant genes and use resveratrol, an AhR antagonist, to revert resistance in mel
Externí odkaz:
https://doaj.org/article/e059e48b1f30450aba786bdcd533d146
Autor:
David Gilot, Marie-Dominique Galibert
Publikováno v:
Molecular & Cellular Oncology, Vol 5, Iss 1 (2018)
microRNA (miRNA) are critical post-transcriptional regulators and key players in diseases development. We demonstrated that non-canonical microRNA Responsive Elements (here MRE-16) could sequester miR-16, dampening miR-16 tumor suppressor function. W
Externí odkaz:
https://doaj.org/article/a62d8c7896b74aa099222de634511dc3
Autor:
Amine Bouafia, Sébastien Corre, David Gilot, Nicolas Mouchet, Sharon Prince, Marie-Dominique Galibert
Publikováno v:
PLoS Genetics, Vol 10, Iss 5, p e1004309 (2014)
Genomic instability is a major hallmark of cancer. To maintain genomic integrity, cells are equipped with dedicated sensors to monitor DNA repair or to force damaged cells into death programs. The tumor suppressor p53 is central in this process. Here
Externí odkaz:
https://doaj.org/article/d16cd6faf2054649a802fb6de033a131
Autor:
David Gilot, Nolwenn Le Meur, Fanny Giudicelli, Marc Le Vée, Dominique Lagadic-Gossmann, Nathalie Théret, Olivier Fardel
Publikováno v:
PLoS ONE, Vol 6, Iss 3, p e18261 (2011)
The aryl hydrocarbon receptor (AhR) is a transcription factor activated by several environmental pollutants, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and involved in carcinogenesis and various physiological processes, including immune resp
Externí odkaz:
https://doaj.org/article/d9020e2943854eb18e0c9d2d57c856d3
Autor:
Jabbar Khan, Frédéric Ezan, Jean-Yves Crémet, Alain Fautrel, David Gilot, Marine Lambert, Christelle Benaud, Marie-Bérengère Troadec, Claude Prigent
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e26512 (2011)
Aurora kinases belong to a conserved family of serine/threonine kinases key regulators of cell cycle progression. Aurora-A and Aurora-B are expressed in somatic cells and involved mainly in mitosis while Aurora-C is expressed during spermatogenesis a
Externí odkaz:
https://doaj.org/article/dedfd6933cda4aa382289b011f5ee607
Autor:
Anne Sophie Neyroud, Joëlle Rudinger-Thirion, Magali Frugier, Lisa G. Riley, Maud Bidet, Linda Akloul, Andrea Simpson, David Gilot, John Christodoulou, Célia Ravel, Andrew H. Sinclair, Marc-Antoine Belaud-Rotureau, Elena J. Tucker, Sylvie Jaillard
Publikováno v:
European Journal of Human Genetics
European Journal of Human Genetics, 2023, 31 (4), pp.453-460. ⟨10.1038/s41431-022-01252-1⟩
European Journal of Human Genetics, 2023, 31 (4), pp.453-460. ⟨10.1038/s41431-022-01252-1⟩
International audience; Premature ovarian insufficiency (POI) affects 1 in 100 women and is a leading cause of female infertility. There are over 80 genes in which variants can cause POI, with these explaining only a minority of cases. Whole exome se
Autor:
Elena J. Tucker, Niklas Gutfreund, Marc‐Antoine Belaud‐Rotureau, David Gilot, Tiffany Brun, Brianna L. Kline, Katrina M. Bell, Mathilde Domin‐Bernhard, Camille Théard, Philippe Touraine, Gorjana Robevska, Jocelyn van van den Bergen, Katie L. Ayers, Andrew H. Sinclair, Volker Dötsch, Sylvie Jaillard
Publikováno v:
Human Mutation
Human Mutation, 2022, 43 (10), pp.1443-1453. ⟨10.1002/humu.24432⟩
Human Mutation, 2022, 43 (10), pp.1443-1453. ⟨10.1002/humu.24432⟩
International audience; Premature ovarian insufficiency (POI) is a leading form of female infertility, characterised by menstrual disturbance and elevated follicle-stimulating hormone before age 40. It is highly heterogeneous with variants in over 80